Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are
 currently participating in a clinical trial which is closing. This research study is studying
 Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657
This research study is an Expanded Access Trial, which is a way to provide an investigational
 therapy to individuals who are not eligible to receive that therapy in a clinical trial, but
 have a serious or life-threatening illness for which other treatments are not available.

 The purpose of this expanded access program is to treat participants diagnosed with relapsed
 or refractory multiple myeloma with an investigational drug called ulocuplumab.

 Participants enrolled in the program will receive ulocuplumab with lenalidomide and
 dexamethasone or ulocuplumab with bortezomib and dexamethasone. Ulocuplumab is supposed to
 kill myeloma cells.

 Lenalidomide, which is also known as Revlimid® and Bortezomib, which is also known as
 Velcade®, are approved by the FDA for treatment of Multiple Myeloma. Dexamethasone, also
 known as Decadron®, is also approved by the FDA for other treatments. It is a type of steroid
 medication that fights inflammation.
Inclusion Criteria:

 -  Signed informed consent document

 -  Must be currently participating on protocol 11-240 (DFCI)/ CA 212-002(BMS), tolerating
 therapy, and still receiving benefit from treatment.

 Exclusion Criteria:

 -  Prior exposure to Ulocuplumab other than in DFCI Protocol 11-240 (BMS protocol
 CA212-002) or any other any other CXCR4 inhibitor (small molecule within 14 days;
 antibody against CXCR4 within 10 weeks).